Compounds > neferine
Page last updated: 2024-09-04

neferine and imatinib mesylate

neferine has been researched along with imatinib mesylate in 3 studies

Compound Research Comparison

Studies
(neferine)		Trials
(neferine)		Recent Studies (post-2010)
(neferine)		Studies
(imatinib mesylate)		Trials
(imatinib mesylate)		Recent Studies (post-2010) (imatinib mesylate)
165012011,4779605,773

Protein Interaction Comparison

ProteinTaxonomyneferine (IC50)imatinib mesylate (IC50)
Tyrosine-protein kinase ABL1Homo sapiens (human)0.31
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, J; Qin, Q; Xiao, XB; Xie, ZX; Zhu, Y1
Chen, XP; Li, YJ; Min, H; Qin, Q; Xiao, YH; Yang, ZS1
Dong, Q; Ouyang, W; Qin, Q; Xiao, Y; Zhang, Y1

Other Studies

3 other study(ies) available for neferine and imatinib mesylate

ArticleYear
[Effect of neferine on the chemotherapic sensitivity of STI 571 to K562/A02 cells].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2005, Volume: 30, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Benzylisoquinolines; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2005
Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Benzylisoquinolines; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrimidines; RNA, Messenger

2011
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
    Journal of food science, 2019, Volume: 84, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lotus

2019